Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis

Published:2023-03 Issue: Volume:71 Page:104581
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Pipek Leonardo Zumerkorn^ORCID,Mahler João Vitor,Nascimento Rafaela Farias Vidigal,Apóstolos-Pereira Samira Luísa,Silva Guilherme Diogo,Callegaro Dagoberto

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference26 articles.

1. Early predictors of conversion to secondary progressive multiple sclerosis;Barzegar;Mult. Scler. Relat. Disord.,2021

2. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis;Brown;JAMA,2019

3. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study;Buron;Neurology,2020

4. Escalation vs. early intense therapy in multiple sclerosis;Casanova;J. Pers. Med.,2022

5. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies;Cree;Mult. Scler. Relat. Disord.,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?;Current Neuropharmacology;2024-07

2. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14

3. Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria;Journal of Neurology;2024-03-02

4. Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review;Current Pharmaceutical Design;2024-02

5. Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany;Therapeutic Advances in Neurological Disorders;2024-01